Publications by authors named "N Favrolt"
Background: Trastuzumab emtansine has been recently suspected to be associated with the development of pulmonary arterial hypertension (PAH).
Research Question: Is there an association between trastuzumab, trastuzumab emtansine, or trastuzumab deruxtecan and the development of PAH?.
Study Design And Methods: Characteristics of incident PAH cases treated with trastuzumab, trastuzumab emtansine, or trastuzumab deruxtecan were analyzed from the French PH Registry, the VIGIAPATH program, concurrently with a pharmacovigilance disproportionality analysis using the World Health Organization pharmacovigilance database using a broad definition of pulmonary hypertension (PH) and a narrow definition of PAH.
Background: Despite its known cardiac and lung toxicities, the chemotherapy drug gemcitabine has only rarely been associated with pulmonary hypertension (PH), and the underlying mechanism remains unclear. The objective of the present study was to assess the association between gemcitabine and PH.
Methods: We identified incident cases of precapillary PH confirmed by right heart catheterisation in patients treated with gemcitabine from the French PH Registry between January 2007 and December 2022.
Article Synopsis
- This study investigates the incidence and treatment of malignant central airway obstruction (MCAO) in patients with metastatic non-bronchogenic solid cancers (NBC), revealing that 18% of a large cohort experienced this complication.
- It identifies key prognostic factors influencing survival post-therapeutic bronchoscopy (TB), such as histology, performance status, and previous treatments.
- The findings suggest that TB effectively alleviates symptoms and prolongs survival for these patients, highlighting the need for timely referrals for bronchoscopic interventions.
Background And Objective: EpiGETIF is a web-based, multicentre clinical database created in 2019 aiming for prospective collection of data regarding therapeutic rigid bronchoscopy (TB) for malignant central airway obstruction (MCAO).
Methods: Patients were enrolled into the registry from January 2019 to November 2022. Data were prospectively entered through a web-interface, using standardized definitions for each item.